Literature DB >> 30524029

90Y TOF-PET based EUD reunifies patient survival prediction in resin and glass microspheres radioembolization of HCC tumours.

P d'Abadie1, M Hesse, F Jamar, R Lhommel, S Walrand.   

Abstract

Clinical studies reported a twofold ratio between the efficacies per Gy of resin versus glass spheres. Our aim is to investigate whether this difference could result from the different degrees of heterogeneity in sphere distribution between the two medical devices. The 90Y TOF-PET based equivalent uniform doses (EUD) was used for this purpose. 58 consecutive HCC radioembolizations were retrospectively analyzed. Absorbed doses D and Jones-Hoban EUD in lesions were computed. Radioembolization efficacy was assessed using Kaplan-Meier survival curves. In order to match together the glass and resin spheres survival curves using a 40 Gy-threshold, an efficacy factor of 0.73 and 0.36 has to be applied on their absorbed dose, respectively. Using EUD, a nice matching between glass and resin survival curves was obtained with a better separation of the responding and not responding survival curves. The results clearly support the fact that the activity heterogeneity observed in 90Y TOF-PET post radioembolization does not only result from statistical noise, but also reflects the actual heterogeneity of the spheres distribution. Use of EUD reunifies the efficacy of the two medical devices.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30524029     DOI: 10.1088/1361-6560/aaf205

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  10 in total

1.  Prediction of Tumor Control in 90Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics.

Authors:  Yuni K Dewaraja; Theresa Devasia; Ravi K Kaza; Justin K Mikell; Dawn Owen; Peter L Roberson; Matthew J Schipper
Journal:  J Nucl Med       Date:  2019-05-30       Impact factor: 10.057

2.  TCP post-radioembolization and TCP post-EBRT in HCC are similar and can be predicted using the in vitro radiosensitivity.

Authors:  Philippe d'Abadie; Stephan Walrand; Michel Hesse; Ivan Borbath; Renaud Lhommel; François Jamar
Journal:  EJNMMI Res       Date:  2022-07-08       Impact factor: 3.434

3.  Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.

Authors:  Matthew Walton; Ros Wade; Lindsay Claxton; Sahar Sharif-Hurst; Melissa Harden; Jai Patel; Ian Rowe; Robert Hodgson; Alison Eastwood
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

4.  Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After 90Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity.

Authors:  Matthew M Cousins; Theresa P Devasia; Christopher M Maurino; Justin Mikell; Matthew J Schipper; Ravi K Kaza; Theodore S Lawrence; Kyle C Cuneo; Yuni K Dewaraja
Journal:  J Nucl Med       Date:  2021-09-09       Impact factor: 11.082

5.  Yttrium-90 TOF-PET-Based EUD Predicts Response Post Liver Radioembolizations Using Recommended Manufacturer FDG Reconstruction Parameters.

Authors:  Michel Hesse; Philipe d'Abadie; Renaud Lhommel; Francois Jamar; Stephan Walrand
Journal:  Front Oncol       Date:  2021-10-05       Impact factor: 6.244

6.  Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose-Response Analysis with Two Radiological Methods.

Authors:  Chiara Romanò; Stefania Mazzaglia; Marco Maccauro; Carlo Spreafico; Alejandro Gabutti; Gabriele Maffi; Carlo Morosi; Tommaso Cascella; Marta Mira; Maria Chiara De Nile; Gianluca Aliberti; Giovanni Argiroffi; Valentina Fuoco; Sherrie Bhoori; Consuelo Zanette; Alfonso Marchianò; Ettore Seregni; Vincenzo Mazzaferro; Carlo Chiesa
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

Review 7.  Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria.

Authors:  Philippe d'Abadie; Stephan Walrand; Renaud Lhommel; Michel Hesse; Ivan Borbath; François Jamar
Journal:  Curr Oncol       Date:  2022-03-29       Impact factor: 3.109

Review 8.  Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects.

Authors:  Philippe d'Abadie; Michel Hesse; Amandine Louppe; Renaud Lhommel; Stephan Walrand; Francois Jamar
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

9.  Methods for selecting the best evidence to inform a NICE technology appraisal on selective internal radiation therapies for hepatocellular carcinoma.

Authors:  Ros Wade; Sahar Sharif-Hurst; Melissa Harden; Matthew Walton; Lindsay Claxton; Robert Hodgson; Alison Eastwood
Journal:  Syst Rev       Date:  2020-08-16

10.  Significant artefactual noise in 90Y TOF-PET imaging of low specific activity phantoms arises despite increased acquisition time.

Authors:  Michel Hesse; Stephan Walrand
Journal:  EJNMMI Phys       Date:  2019-11-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.